Guided Therapeutics (GTHP) Total Current Liabilities (2010 - 2025)

Guided Therapeutics (GTHP) has 16 years of Total Current Liabilities data on file, last reported at $6.6 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities rose 7.81% year-over-year to $6.6 million; the trailing twelve-month figure through Dec 2025 stood at $6.6 million (up 7.81% YoY), and the FY2025 full-year result was $6.6 million, up 7.81% from the prior year.
• Total Current Liabilities improved to $6.6 million in Q4 2025, from $6.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $9.2 million in Q1 2021 to a low of $4.0 million in Q1 2023.
• A 5-year average of $5.7 million and a median of $5.7 million in 2021 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities sank 40.96% in 2022 and surged 33.45% in 2024, its largest moves.
• Tracing GTHP's Total Current Liabilities over 5 years: stood at $5.7 million in 2021, then dropped by 14.49% to $4.9 million in 2022, then fell by 1.23% to $4.8 million in 2023, then climbed by 27.99% to $6.2 million in 2024, then grew by 7.81% to $6.6 million in 2025.
• Business Quant data shows GTHP's Total Current Liabilities at $6.6 million in Q4 2025, $6.5 million in Q3 2025, and $6.4 million in Q2 2025.